CJC-1295 ipamorelin dosage calculator

Three molecules, one confusing name

Products sold as "CJC-1295" can be either of two different molecules, and ipamorelin is a third, much smaller one.

The FDA found "at least five distinct" CJC-1295 substances sold under "at least nine different names".^[2] A vial labeled "CJC-1295" does not tell you which one it holds, and the difference matters: in its trial the DAC version had a half-life of 5.8 to 8.1 days.^[8] Molecular weights are from the FDA briefing documents.^[2][3]

Regulatory status

Neither peptide is FDA-approved, and the FDA's advisory committee voted against compounding every form of both in 2024.

• FDA safety wording, CJC-1295: the FDA "has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction."^[4]
• FDA safety wording, ipamorelin: it "contains unnatural amino acids, which add to the complexity of peptide characterization", and a published study "identified serious adverse events including death when ipamorelin was administered intravenously".^[4]
• Ipamorelin, outsourcing facilities: still on the 503B Category 2 list.^[5]
• Imports: FDA Import Alert 66-41 lists ipamorelin, including shipments declared as amino acids.^[13]
• Enforcement: a 2020 warning letter told a compounder CJC-1295 was not eligible for compounding,^[14] and 2026 letters to research-peptide sellers cited products blending ipamorelin with tesamorelin.^[15][16]
• Sport: WADA 2026 S2.2.4 names CJC-1295 and ipamorelin; both are prohibited at all times.^[18] More on the peptides banned in sport page.

What the human evidence says

Human data are limited to small studies of CJC-1295 with DAC in healthy adults and of intravenous ipamorelin after surgery; the combination has never been tested.

Two gaps stand out. No study of CJC-1295 without DAC and no study of ipamorelin under the skin, the forms and route most often sold, were found by the FDA.^[2][3] And no trial has combined the two. Amounts in these studies are per kilogram of body weight, given under medical supervision; they are not totals and not recommendations.

CJC-1295 and ipamorelin side effects in the trials

In the published trials, CJC-1295 with DAC commonly caused injection-site reactions, flushing and headache, and intravenous ipamorelin was linked to low potassium and sleep problems more often than placebo.

These are side effects from small trials of specific forms and routes. For the combination sold together, and for ipamorelin under the skin, there are no published data. How these peptides compare with sermorelin and tesamorelin is on the HGH peptides page.

Units and nanomoles

One ipamorelin study reported amounts in nanomoles per kilogram,^[3] so converting between mass and moles is useful when reading them. The three molecules differ almost fivefold in weight:

For a vial holding both peptides, each unit holds both. The table shows what 10 units contain for equal-ratio vials; the arithmetic is explained on the blend calculator page.

Example: 2 mg of a single peptide in 2 mL is 10 mcg per unit, so 100 mcg is 10 units.

Other peptide pages

The peptides most often looked up alongside this one. Each page gives that peptide's FDA status, compounding status and published human evidence, with sources; the status table has all 23 in one place.

• TesamorelinFDA-approved Egrifta SV and Egrifta WR. Labeled doses, diluents and volumes.
• SermorelinDiscontinued Once sold as Geref. Discontinued in 2008, not for safety reasons.
• AOD-9604Not approved Growth hormone fragment. Obesity trials failed; committee voted 0–12.
• GHRP-6Not approved Growth hormone-releasing hexapeptide. On FDA 503B Category 2.
• HexarelinNot approved GHRP-6 plus one methyl group. Studied in the 1990s, never approved.
• BPC-157Not approved 15-amino-acid peptide. Human data: a few tiny, uncontrolled studies.